Clinical Distribution and Molecular Basis of Traditional Chinese Medicine ZHENG in Cancer (Need evidence-based, prospective, peer-reviewed studies)

http://www.ncbi.nlm.nih.gov/pubmed/22829858

Evid Based Complement Alternat Med. 2012;2012:783923. Epub 2012 Jul 4.

Clinical Distribution and Molecular Basis of Traditional Chinese Medicine ZHENG in Cancer.

Chen Z, Wang P.

Source

Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.

Abstract

In traditional Chinese medicine (TCM) clinical practice, ZHENG (also known as syndrome) helps to guide design of individualized treatment strategies. In this study, we investigated the clinical use of ZHENG in TCM-treated cancer patients by systematically analyzing data from all relevant reports in the Chinese-language scientific literature. We aimed to determine the clinical ZHENG distributions in six common cancers (lung, liver, gastric, breast, colorectal, and pancreatic) with the expectation of uncovering a theoretical basis for TCM ZHENG as a clinical cancer treatment. In addition, we also reviewed the molecular basis underlying Xue-Yu (blood stasis), Shi-Re (dampness-heat), Yin-Xu (Yin deficiency), and Pi-Xu (spleen deficiency) ZHENG that are commonly found in cancer patients. The results from our summary study provide insights into the potential utility of TCM ZHENG and may contribute to a better understanding of the molecular basis of TCM ZHENG in cancer.